• This blood test checks for immunoglobulin G (IgG), an antibody that is produced by the body around 10 to 18 days after exposure to COVID-19 infection or after vaccination.
  • Antibody production starts at around 5 days post-infection and reaches peak concentrations at 2 weeks for IgM and 3 weeks for IgG.
  • This assay is intended for the quantitative detection of anti-SARS-CoV-2 IgG antibodies from serum, plasma, or fingertip blood samples.
  • Targets the spike protein 1 (S1) RBD in the SARS-CoV-2 genome.
  • CE/IVD Marked
  • FDA/EUA Filed
  • Validated in CLIA-certified laboratory as an LDT
  • Sample type: Capillary Blood Finger Prick
  • No cross-reactivity with other viruses
  • Clinical specificity: 98.25%
  • Clinical sensitivity: 96.77%